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Abstract
Purpose: To assess the cost effectiveness of adding cetuximab to platinum-based chemotherapy in first-line treatment of
patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) from the perspective of the
Canadian public healthcare system.
Methods: We developed a Markov state transition model to project the lifetime clinical and economic consequences of
recurrent or metastatic HNSCC. Transition probabilities were derived from a phase III trial of cetuximab in patients with
recurrent or metastatic HNSCC. Cost estimates were obtained from London Health Sciences Centre and the Ontario Case
Costing Initiative, and expressed in 2011 CAD. A three year time horizon was used. Future costs and health benefits were
discounted at 5%.
Results: In the base case, cetuximab plus platinum-based chemotherapy compared to platinum-based chemotherapy alone
led to an increase of 0.093 QALY and an increase in cost of $36,000 per person, resulting in an incremental cost effectiveness
ratio (ICER) of $386,000 per QALY gained. The cost effectiveness ratio was most sensitive to the cost per mg of cetuximab
and the absolute risk of progression among patients receiving cetuximab.
Conclusion: The addition of cetuximab to standard platinum-based chemotherapy in first-line treatment of patients with
recurrent or metastatic HNSCC has an ICER that exceeds $100,000 per QALY gained. Cetuximab can only be economically
attractive in this patient population if the cost of cetuximab is substantially reduced or if future research can identify
predictive markers to select patients most likely to benefit from the addition of cetuximab to chemotherapy.
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Introduction
There were approximately 4550 new cases of head and neck
cancers (excluding thyroid cancer and melanoma) diagnosed in
Canada in 2010 [1]. Treatment may include surgery and definitive
radiation therapy, with or without concurrent chemotherapy. The
main manifestations of treatment failure are loco-regional recur-
rences and distant metastatic disease. Management of recurrent or
metastaticheadandnecksquamouscellcarcinoma(HNSCC)thatis
inoperable and not amenable to re-irradiation usually involves
systemic chemotherapy, with platinum-based combinations being
the most commonly used regimens [2]. Regardless of the choice of
chemotherapy, this patient population has a poor prognosis with a
median survival of six to eight months [3].
Cetuximab (Erbitux) is a chimeric IgG1 monoclonal antibody
that competitively inhibits transforming growth factor-a (TGF-a)
ligand from binding to epidermal growth factor receptor (EGFR),
resulting in inhibition of tumour growth, invasion and metastasis,
DNA damage repair and angiogenesis [4,5,6].
Cetuximab is the first targeted therapy to demonstrate a
significant survival benefit in patients with locally advanced
HNSCC [7] and recurrent or metastatic HNSCC [8]. Cetuximab
therapy has been recently adopted into clinical practice and
funded in most Canadian provinces for patients with locally
advanced HNSCC who are platinum-ineligible or elderly because
it offers an alternative that is recognized to be superior to
radiotherapy alone [9]. A similar adoption strategy has been taken
in the United Kingdom [10]. Cetuximab in the recurrent or
metastatic HNSCC setting has not yet found its way into clinical
practice in Canada [11].
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motherapy significantly improved efficacy outcomes compared
with platinum-based chemotherapy alone in a randomized phase
III trial in patients with recurrent or metastatic HNSCC (the
EXTREME study-Erbitux in First-Line Treatment of Recurrent
or Metastatic Head and Neck Cancer) [8]. The addition of
cetuximab to platinum-based chemotherapy (cisplatin or carbo-
platin combined with fluorouracil) was associated with a 16%
increase in response rate (P,0.001), a 2.3 month increase in
progression-free survival (PFS) (P,0.001), and a 2.7 month
increase in overall survival (OS) from a median of 7.4 months to
10.1 months (P=0.036), compared to platinum-based chemother-
apy alone [8]. Moreover, the addition of cetuximab to platinum-
based chemotherapy did not adversely affect health-related quality
of life, as assessed using validated, multidimensional instruments,
compared with chemotherapy alone [8]. In the same trial,
protocol-defined sub-group analyses indicated that the addition
of cetuximab to platinum based chemotherapy is associated with
clinical benefits in the majority of the sub-groups investigated and
could not demonstrate greater survival benefits to some subgroups
than to others [8]. Therefore, the clinical evidence from the
EXTREME trial suggests that the combination of cetuximab with
platinum-based chemotherapy is the most active first-line treat-
ment regimen currently available for patients with recurrent or
metastatic HNSCC and strongly supports the use of this regimen
as a standard treatment approach in this patient setting [8].
Recently, the United States Food and Drug Administration (FDA)
has approved cetuximab for use in combination with platinum-
based chemotherapy for the treatment of recurrent or metastatic
HNSCC. The approval was based primarily on the results of the
EXTREME trial.
Since the introduction of cisplatin for the treatment of recurrent
or metastatic HNSCC approximately 30 years ago, there has been
a little improvement in survival among the patients with this
disease [12,13]. Thus, based on the clinical data from the
EXTREME trial, cetuximab-based therapy is appealing to both
patients and clinicians. According to a recent Canadian analysis,
cetuximab costs approximately $6,500 CAD per patient per
month with all Canadian health system expenses included [14].
The purpose of this study was to assess the cost-effectiveness of
cetuximab plus platinum-based chemotherapy in recurrent or
metastatic HNSCC from the perspective of the Canadian public
healthcare system.
Methods
Model overview
We developed a decision analytic model to estimate the health
and economic consequences of different treatment regimens for
patients with recurrent or metastatic HNSCC (Figure 1; param-
eter estimates are summarized in Tables 1, 2, 3). The model begins
with a decision to treat with cetuximab plus platinum-based
chemotherapy or platinum-based chemotherapy alone (Figure 1a).
Patients receiving platinum-based chemotherapy entered model
‘‘P’’ (Figure 1b) and those receiving cetuximab plus platinum-
based chemotherapy entered model ‘‘C’’ (Figure 1c). Model ‘‘C’’
differs from model ‘‘P’’ in that it has several additional states to
account for cetuximab-related adverse effects (AEs). We modeled
AEs based on those observed in the EXTREME trial [8] and
considered both mild and severe AEs. Mild AEs included grade 1
or 2 infusion-related allergies and skin reactions. Severe AEs
included grade 3 or 4 infusion-related reactions (allergy or
anaphylaxis, dyspnea and hypotension), anorexia, hypomagnese-
mia, sepsis and skin reactions.
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CEA of Cetuximab for Head and Neck Cancer
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CEA of Cetuximab for Head and Neck Cancer
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38557Figure 1. Diagram of the decision model. 1a Decision about choice of treatment regimen. 1b Diagram of Markov model ‘‘P’’{. 1c Diagram of
Markov model ‘‘C’’{. Footnotes to Figure 1: {Patients entering Markov model ‘‘P’’ start the model in the stable state and remain in the stable state
unless they relapse (progression or death). Patients who progress remain in the progression state or transition to the death state. {Patients entering
Markov model ‘‘C’’ start the model in the stable state with no AE. During the first cycle patients may develop mild or any severe AE. After the first
cycle, patients may remain in stable with no or mild AE unless they develop severe anorexia (A), hypomagnesemia (HG) or sepsis (S), progress or die.
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38557Model ‘‘P’’ simulated monthly transitions among the following
distinct health states: (1) Stable (no progression); (2) Progression; (3)
Dead. Model ‘‘C’’ simulated monthly transitions among the
following distinct health states: (1) Stable with no AE; (2) Stable
with mild AE; (3) Stable with severe dyspnea; (4) Stable with severe
allergy or anaphylaxis; (5) Stable with severe hypotension; (6)
Stable with severe skin reactions; (7) Stable with severe sepsis (8)
Stable with severe hypomagnesemia; (9) Stable with severe
anorexia; (10) Progression; (11) Dead. We assumed that transitions
to any of the stable states with AE except those with severe
anorexia, hypomagnesemia and sepsis would only occur in the first
month of treatment since these reactions are most likely to start
developing following the initial infusion of cetuximab [8]. We
assumed that severe anorexia, hypomagnesemia or sepsis could
occur any time while the patient still received cetxuximab [8]. We
assumed that patients who develop any severe AE or experience
progression would stop receiving cetuximab in accordance with
Canadian guidelines for the administration of cetuximab [15]. We
used a time horizon of 3 years (36 months). This time horizon was
appropriate since the overall survival probabilities at 2 years in the
EXTREME trial were 18% in the cetuximab plus platinum-based
chemotherapy arm and 16% in the platinum-based chemotherapy
alone arm, and projected survival beyond 3 years was less than 1%
in both groups.
We used TreeAge Software to produce and evaluate the
decision analytic model, using a half cycle correction [16].
Transition probabilities
For both models we derived time-dependent monthly transition
probabilities from the ‘‘stable’’ to ‘‘progression’’ state and from the
‘‘progression’’ to ‘‘dead’’ state, respectively, using the Kaplan-
Meier curves of progression free survival and overall survival over
two years of follow up reported in the EXTREME trial [8]. We
used sex-specific life tables for Ontario to adjust the derived
transition probabilities of overall survival to account for death by
other causes [17]. We assumed that transitions from ‘‘stable’’ to
‘‘dead’’ were from causes other than HNSCC and we estimated
these transition probabilities using Ontario sex-specific life tables
[17] accounting for the sex balance observed in the EXTREME
trial [8]. To extrapolate the transition probabilities for 1 year
beyond the period of the EXTREME trial, we assumed the
observed average monthly transition probabilities from ‘‘stable’’ to
‘‘progression’’ and from ‘‘progression’’ to ‘‘dead’’ during the
second year of follow up in the EXTREME trial to be constant
over the extrapolated third year.
We derived the incremental AE rates for cetuximab plus
platinum-based chemotherapy versus platinum-based chemother-
apy treated patients from the adverse-event profiles provided in
the EXTREME trial.
Cost and Utility Values
In Canada, there is no publicly available source for the cost of
cetuximab [18]. The Patented Medicine Prices Review Board
(PMPRB) is a government agency in Canada which regulates the
prices of drugs that are still under patent and have no generic
substitutes. PMPRB guidelines stipulate that the price in Canada
cannot exceed the median cost among a set of comparison
countries [18]. The cost of cetuximab in 2005 ranged from $2.94
to $6.73 per mg in countries that were reviewed by the PMPRB
with a median cost of $3.49 per mg. As of March 2012 cetuximab
is reimbursed by Cancer Care Ontario at $3.46 per mg [19]. In
our base case analysis we used $3.46 per mg of cetuximab.
The costs of management of mild AEs were obtained from
internal case costing conducted by the London Regional Cancer
Program, London, Canada [20]. We assumed that any severe AE
will result in hospitalization. Hospital costs, based on the Ontario
Case Costing Initiative [21], were applied to the corresponding
severe AEs using the International Classification of Diseases, tenth
revision diagnostic code [22]. All costs are expressed in 2011
CAD.
We assumed that the addition of cetuximab to platinum-based
chemotherapy would not adversely affect health related quality of
life compared with chemotherapy alone as observed in the
EXTREME trial [8]. The baseline utility for stable HNSCC (with
no or mild AE) was 0.65 and for progressing HNSCC was 0.52,
based on estimates supplied by the manufacturer of cetuximab in
its submission to the UK National Institute for Health and Clinical
Excellence [23]. To account for the disutility associated with
severe AEs, we derived disutility estimates for patients with these
events as reported in the literature [24,25,26,27,28,29,30]. We
applied these disutility estimates to the baseline utility for stable
HNSCC to reflect the utility for stable HNSCC with different
severe AEs consistent with methodology described elsewhere [31].
All future costs and utilities were discounted at 5% following
Canadian guidelines [32].
Results
Base-case scenario
In the base case, the overall survival at 3 years in our model
were 0.5% in the cetuximab plus platinum-based chemotherapy
arm and 0% in the platinum-based chemotherapy alone arm.
Cetuximab plus platinum-based chemotherapy compared to
platinum-based chemotherapy alone led to an increase of 0.093
QALY per person and an increase in cost of $36,000 per person,
resulting in an incremental cost effectiveness ratio (ICER) of
$386,000 per QALY gained. For individuals receiving cetuximab
the expected cost per person for cetuximab was $33,360 and the
expected incremental cost of cetuximab plus chemotherapy,
relative to individuals who received chemotherapy only, was
approximately $35,000 per person.
Sensitivity analyses
The model was not sensitive to the disutility associated with
severe AEs, the rates of AEs or the cost of severe AEs. The ICER
remains above $200,000 per QALY when we changed these
variables in one way, two way and three way sensitivity analyses.
When we did not consider quality of life, cetuximab plus platinum-
based chemotherapy compared to platinum-based chemotherapy
alone led to an increase of 0.136 life years (LY) per person,
resulting in an ICER of $265,000 per LY gained. When we used a
time horizon of 2 years (the end of the follow-up period in the
EXTREME trial), the ICER fell slightly to $340,700 per QALY
gained. When we extended the time horizon to 4 and 5 years, our
base case ICER estimates rose slightly to $393,000 per QALY
gained and $395,000 per QALY gained, respectively. In addition,
our results in the base case analysis remained robust when we
Patient who develop any severe AE remain in stable with that AE state unless they progress or die. Patients who progress remain in the progression
state or make transition to the dead state. The cycle length was 1 month. AE=cetuximab-related adverse effects, D= dyspnea, AA= allergy or
anaphylaxis, H= hypotension, SR= skin reactions.
doi:10.1371/journal.pone.0038557.g001
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38557varied the discounting rate for future costs and utilities between 0
to 5%.
We conducted threshold analysis to identify conditions under
which the ICER would fall below $100,000 per QALY gained.
The ICER fell to less than $100,000 per QALY gained if the cost
per mg of cetuximab was reduced by 75% to $0.81/mg (Figure 2).
The ICER fell to less than $100,000 per QALY gained if the
baseline absolute risk of progression in the cetuximab based
strategy was reduced by 65% (Figure 2). In two way sensitivity
analysis, the ICER fell to less than $100,000 per QALY gained,
when simultaneously, the baseline cost per mg of cetuximab and
risk of progression in the cetuximab based strategy were reduced
by 40% and 35% respectively (Figure 2).
We also performed a probabilistic sensitivity analysis and value-
of-information analysis. We simultaneously varied all parameters
(probabilities, utilities and costs) using appropriate distributions
(Tables 1, 2, 3). Using a willingness to pay threshold of
$100,000 per QALY gained, we found that the cetuximab based
strategy was the preferred strategy in only 1% of simulations
(Figure 3a). The cetuximab based strategy becomes equally
favored at a willingness to pay of approximately $350,000 per
QALY (Figure 3b). In addition, we performed value-of-informa-
tion analysis [33]. Using a willingness to pay threshold of
$100,000 per QALY gained, we found no value of removing all
statistical uncertainty related to the benefit of cetuximab.
Discussion
We developed a decision-analytic model to assess the cost
effectiveness of cetuximab plus platinum-based chemotherapy
versus platinum-based chemotherapy alone in first-line treatment
of recurrent or metastatic HNSCC. In the base case, we estimated
that cetuximab has an ICER of $386,000 per QALY gained. Our
ICER estimate is significantly higher than $100,000 per QALY
gained, a level which has been suggested in Canada to define
‘‘weak evidence in support of adoption’’ [34], and also above levels
of recently rejected cancer treatments. However, funding decisions
are not made solely on the basis of cost effectiveness, and other
considerations such as need, equity and total budget impact may
also be important to policy makers [35,36,37,38].
Findings from the EXTREME trial indicate that adding
cetuximab to platinum-based chemotherapy in first-line treat-
ment of recurrent or metastatic HNSCC can lead to a modest
but statistically significant and clinically meaningful survival
benefit [8]. However, our analysis suggests that it may be
challenging for public payers to fund cetuximab based on the
current evidence.
Figure 2. Sensitivity of the ICER to the cost of cetuximab per
mg and the risk of progression in the cetuximab based
strategy.
doi:10.1371/journal.pone.0038557.g002
Figure 3. Incremental cost-effectiveness scatter plot and cost
effectiveness acceptability curves of platinum-based chemo-
therapy plus cetuximab versus platinum-based chemotherapy
alone. Each graph was based on 10000 replicates. 3a Incremental cost-
effectiveness scatter plots. 3b Cost effectiveness acceptability curves.
doi:10.1371/journal.pone.0038557.g003
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setting, the clinical effectiveness and cost-effectiveness of cetux-
imab has been previously demonstrated in locally advanced
HNSCC [24]. Favorable ICER values were shown for patients
who are medically unsuitable for concurrent platinum-based
chemotherapy, with Karnofsky performance status (KPS) of 90%
or better, or over the age of 70 years, with values ranging between
J7,538 ($10,264 CAD) and J10,836 ($14,754 CAD) per QALY
gained in Europe [24] and $19,740 CAD per QALY in Canada
[39]. In those analyses, limiting cetuximab administration to
patients who were most likely to benefit may have led to more
favorable cost-effectiveness ratios. Consequently, cetuximab in
combination with radiotherapy has been approved for reimburse-
ment for these patient groups in the UK [10,40] and Canada
[41,42]. More recent data suggest that no overall survival benefit is
apparent in older patients, and these reimbursement decisions may
warrant review [43].
Predictive biomarkers could improve cost effectiveness by
selecting patients most likely to benefit from the addition of
cetuximab to chemotherapy. This has been demonstrated in
patients with other types of cancer such as breast [44] and
colorectal cancer [45,46]. For instance, Mittman et al [18] have
shown that restricting cetuximab to advanced colorectal cancer
patients with wild-type KRAS reduces the ICER of cetuximab
over best supportive care alone from $199,742 CAD per QALY to
$120,061CAD per QALY. Consequently, cetuximab has been
approved for reimbursement for wild-type KRAS advanced
colorectal cancer patients in Canada. Subgroup analyses in the
EXTREME trial suggest that cetuximab plus platinum-based
chemotherapy offered greater survival benefits to some subgroups
than others [11]. Age less than 65 years, KPS of 80 or more, and
primary tumour site other than hypopharynx appeared to be
favorable for improved progression free survival and overall
survival with cetuximab-based treatment. However sub-group
treatment interaction tests identified only one significant interac-
tion, which was between treatment and the primary tumour site
(P=0.03), and due to the lack of adjustment for multiple testing
and the small numbers of patients in some of the subgroups, the
authors were not able to state with certainty that some groups did
not benefit from cetuximab or to suggest the degree of benefit from
cetuximab across the studied subgroups [11].
Analysis of the EXTREME trial demonstrated that among
patients receiving cetuximab plus platinum-based chemotherapy,
the development of grade 1 or higher skin reactions at a given time
was associated with a 23% reduction in the risk of death and a
20% reduction in the risk of progression, compared with patients
not developing skin reactions by that time [8]. However, as every
patient needs to be treated to determine skin reaction, this is an
inefficient biomarker, and may simply be a pharmacodynamics
biomarker of drug dose (i.e., less rash indicates the need for higher
cetuximab dose). Profiling colorectal tumours for wild type versus
mutated KRAS gene has been valuable for selecting patients who
are unlikely to benefit with cetuximab or panitumumab
[44,45,46]; however, these KRAS mutations are uncommon in
HNSCC [47,48]. EGFR gene copy number as determined by
fluorescence in situ hybridization (FISH) does not appear to
influence response to cetuximab in recurrent or metastatic
HNSCC [8]. Therefore, there is no current evidence to suggest
any particular clinical characteristic or biomarker is of practical
use for tailoring treatment with cetuximab in patients with
recurrent or metastatic HNSCC.
As such, our analysis assumed all patients with recurrent or
metastatic disease are suitable candidates for the treatment with
cetuximab. Our sensitivity analyses suggest that cetuximab is too
expensive for its modest clinical benefits when added to platinum-
based chemotherapy in this patient setting. Thus, only a reduction
in the cost of cetuximab can lead to favorable cost effectiveness
ratios at the present time. Results of value-of-information analysis
indicated that future research on cetuximab in the recurrent or
metastatic setting where all patients are considered suitable
candidates (i.e., trials in which there are no adequate selection
criterion) for the treatment with cetuximab such as the
EXTREME study may not have a large societal impact, especially
when willingness to pay levels of recently accepted cancer
treatments are considered. Thus, the identification of predictive
markers to better define subgroups of patients with recurrent or
metastatic HNSCC for whom cetuximab plus platinum-based
chemotherapy may offer either greater or less survival benefits
than others should be a priority.
Our analysis has limitations. The health effects data used in this
economic evaluation were generated from a single clinical trial
which may not reflect the experience of broader population of
patients with recurrent or metastatic HNSCC in Canada.
However, only one randomized phase III trial exists [8]. As most
cancer treatments are less effective and more toxic when
generalized to clinical practice, our ICER estimate likely
represents a ‘‘best case’’ scenario. There also may be uncertainty
around the utility values used in our model. NICE considered the
quality of life collected and reported in the EXTREME trial as
limited. This could have an effect on our estimated ICERs but
varying these values in sensitivity analyses had minimal effects.
Conclusion
In the base case, the ICER of cetuximab exceeded $100,000 per
QALY gained. Compared with other possible uses of public health
care funds in Canada, the addition of cetuximab to platinum-
based chemotherapy does not appear to provide good value for
money in first-line treatment of patients with recurrent or
metastatic HNSCC. However, cetuximab could be economically
attractive in this patient population if its cost was reduced by at
least 75% or if predictive biomarker were identified that could
limit the use of cetuximab to those who are expected to most likely
benefit.
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